Barclays PLC Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Barclays PLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 7.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 298,445 shares of the biopharmaceutical company's stock after purchasing an additional 20,880 shares during the quarter. Barclays PLC owned about 0.18% of ACADIA Pharmaceuticals worth $5,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in ACADIA Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 13,947,640 shares of the biopharmaceutical company's stock valued at $255,939,000 after acquiring an additional 104,444 shares during the last quarter. SG Americas Securities LLC lifted its position in ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock valued at $45,576,000 after purchasing an additional 1,966,607 shares during the period. Norges Bank purchased a new position in shares of ACADIA Pharmaceuticals during the 4th quarter valued at about $25,555,000. Renaissance Technologies LLC boosted its stake in shares of ACADIA Pharmaceuticals by 204.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock worth $22,507,000 after buying an additional 823,333 shares during the last quarter. Finally, Rockefeller Capital Management L.P. raised its position in ACADIA Pharmaceuticals by 2.1% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,163,455 shares of the biopharmaceutical company's stock valued at $21,349,000 after acquiring an additional 23,521 shares in the last quarter. 96.71% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ACAD. StockNews.com upgraded ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, March 8th. HC Wainwright reissued a "buy" rating and set a $27.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, February 27th. Morgan Stanley reaffirmed an "equal weight" rating and set a $20.00 target price on shares of ACADIA Pharmaceuticals in a research note on Friday, March 7th. UBS Group reduced their target price on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating on the stock in a research report on Monday. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They issued a "hold" rating and a $22.00 target price on the stock. Eight research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $23.87.

ACADIA Pharmaceuticals Stock Up 0.1 %

Shares of NASDAQ ACAD traded up $0.01 during mid-day trading on Thursday, hitting $14.61. 346,855 shares of the company were exchanged, compared to its average volume of 1,844,713. The stock has a 50 day simple moving average of $16.32 and a 200-day simple moving average of $16.92. ACADIA Pharmaceuticals Inc. has a 1-year low of $13.40 and a 1-year high of $20.68. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of 18.82 and a beta of 0.54.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Mark C. Schneyer sold 3,171 shares of the business's stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $17.05, for a total transaction of $54,065.55. Following the transaction, the executive vice president now owns 56,889 shares in the company, valued at approximately $969,957.45. The trade was a 5.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Elizabeth A. Garofalo sold 4,919 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $18.23, for a total value of $89,673.37. Following the completion of the sale, the director now directly owns 17,595 shares of the company's stock, valued at $320,756.85. This represents a 21.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,169 shares of company stock worth $242,686. 28.30% of the stock is owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.